10:20 AM EDT, 05/07/2026 (MT Newswires) -- Blackstone's (BX) life sciences unit said Thursday it will invest $250 million in Anagram Therapeutics to help the biopharma company advance the development, approval, and launch of its ANG003 therapy for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis.

ANG003 has demonstrated positive clinical data in people with exocrine pancreatic insufficiency due to cystic fibrosis, according to a statement.

Price: 123.10, Change: -1.59, Percent Change: -1.28